Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...

Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just ...

【製薬・バイオ銘柄 入門解説シリーズ 第2弾 第10回／全12回】 はじめに Recursion Pharmaceuticals（RXRX）は、ロボットが自動で行う大量の実験と、AIによる分析を組み合わせて、新しい薬の候補を見つけようとしている会社です。大手製薬会社Roche（傘下のGenentech）やSanofiと提携し、これまでに合計3億ドルを超える一時金を受け取ってきました。一方で、売上は ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...

The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Recursion is a technique in programming where a function calls itself to solve a problem. It involves breaking down a complex problem into smaller subproblems. Each time the function calls itself, it ...

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...